Frequently Asked Questions

There are no other companies that utilize our electromagnetic/radiofrequency technology against the cognitive impairment of Alzheimer’s Disease. There are several academic institutions in Europe utilizing very different electromagnetic approaches against AD that have not, however, been shown to affect the AD process. Indirect competitive technologies include Transcranial Magnetic Stimulation (tMS), Transcranial Ultrasound (tUS), and Deep Brain Stimulation (DBS). These treatment modalities are very expensive and/or invasive and have thus far not been shown to be effective against AD. Other indirect competitors include several companies (Cognito Therapeutics, Vielight) who are clinically testing photomodulation (LED or infrared light) approaches against AD. Drugs are also indirect competitors; but to date, over 150 drugs have failed to even slow down AD cognitive decline, much less stop or reverse it.

Yes. Following our initial 2010 publication, three independent laboratories published results in 2013, 2015, and 2018 showing that similar electromagnetic treatment to Alzheimer’s mice can provide cognitive benefit and/or substantially decrease Alzheimer’s neuropathology. In addition, our own pre-clinical studies were performed in collaboration with seven independent laboratories, all of which were blind to which mice received treatment and which ones did not. NeuroEM Therapeutics has recently partnered with MegaNano BioTech, Inc. to form a joint NeuroEM/MegaNano Research Laboratory (Research Park, Tampa) for continued basic science research into Transcranial Electromagnetic Treatment against neurologic disorders.

In a combined three clinical studies, our clinical collaborators have now administered TEMT daily for 18 total months within a 2½ year period and have reported no recurring adverse side effects.  Daily diaries kept by the subjects’ caregivers indicated no consistent changes in blood pressure or body temperature associated with TEMT, as well as no recurring changes in daily activities or anxiety level/mood. Moreover, no adverse effects were ascertained at clinical visits and no visible induction of tumors/micro-hemorrhages was evident when comparing pre- vs. post-treatment anatomic MRI scans.

Therefore, TEMT appears to be a safe therapeutic intervention for chronic treatment of AD, at least for the parameters being utilized with the Gen1 device. This is consistent with a large body of epidemiologic literature, including extensive analysis by the National Institute of Environmental Health Sciences (NIEHS), indicating that humans exposed to similar electromagnetic field (EMF) frequencies/power levels via mobile phones have no health or safety risks, no deleterious behavioral/physiologic effects, and no induction of brain cancer, even after many years of EMF exposure.

It is anticipated that, with adequate funding and adherence to our clinical timeline, our Gen2 MemorEM™ device for treating AD could be available for commercialization in late 2025.